US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.52 against a street estimate of 0.41 — a beat of 28.4%.
Analysts rate Liquidia Technologies Inc a buy (9 buy, 0 hold, 1 sell out of 10) with an average price target of $84.88.
| Fund | Stake |
|---|---|
| Farallon Capital Management, L.L.C. | 9.74% |
| Caligan Partners LP | 9.13% |
| BlackRock Inc | 6.17% |
| Findell Capital Management LLC | 3.94% |
| Vanguard Capital Management, LLC | 3.29% |
| Opaleye Management Inc | 2.86% |
| Bank of America Corp | 2.57% |
| Geode Capital Management, LLC | 2.17% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-17 |
| Company announcement · Q2 2026 | 2026-06-08 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Results announced · Q2 2026 | 2026-05-11 |
| Proxy statement · Q2 2026 | 2026-04-24 |
| Annual report FY2025 | 2026-03-05 |
| Results announced · Q1 2026 | 2026-03-05 |
| Quarterly report · Q3 2025 | 2025-11-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Liquidia Technologies Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.